A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression

被引:75
作者
Bloom, Debra D. [1 ]
Centanni, John M. [1 ]
Bhatia, Neehar [2 ]
Emler, Carol A. [2 ]
Drier, Diana [2 ]
Leverson, Glen E. [3 ]
Mckenna, David H., Jr. [4 ]
Gee, Adrian P. [5 ]
Lindblad, Robert [6 ]
Hei, Derek J. [2 ]
Hematti, Peiman [1 ,7 ]
机构
[1] Univ Wisconsin, Dept Med, Madison, WI USA
[2] Univ Wisconsin, Waisman Biomfg, Madison, WI USA
[3] Univ Wisconsin, Dept Surg, Madison, WI USA
[4] Univ Minnesota, Minneapolis, MN USA
[5] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston Methodist Hosp, Houston, TX 77030 USA
[6] EMMES Corp Inc, Rockville, MD USA
[7] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
mesenchymal stromal cells; PACT; potency assay; T-cell suppression; STEM-CELLS; CLINICAL TRANSLATION; IMMUNE-MODULATION; THERAPY; TRANSPLANTATION; HETEROGENEITY; EXPRESSION; RESPONSES; INHIBIT; DIFFERENTIATION;
D O I
10.1016/j.jcyt.2014.10.002
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims. The T-cell suppressive property of bone marrow derived mesenchymal stromal cells (MSCs) has been considered a major mode of action and basis for their utilization in a number of human clinical trials. However, there is no well-established reproducible assay to measure MSC-mediated T-cell suppression. Methods. At the University of Wisconsin-Madison Production Assistance for Cellular Therapy (PACT) Center, we developed an in vitro quality control T-cell suppression immunopotency assay (IPA) that uses anti-CD3 and anti-CD28 antibodies to stimulate T-cell proliferation. We measured MSC-induced suppression of CD4+ T-cell proliferation at various effector-to-target cell ratios with the use of defined peripheral blood mononuclear cells and in parallel compared with a reference standard MSC product. We calculated an IPA value for suppression of CD4+ T cells for each MSC product. Results. Eleven MSC products generated at three independent PACT centers were evaluated for cell surface phenotypic markers and T-cell suppressive properties. Flow cytometry results demonstrated typical MSC cell surface marker profiles. There was significant variability in the level of suppression of T-cell proliferation, with immunopotency assay values ranging from 27% to 88%. However, MSC suppression did not correlate with human leukocyte antigen DR expression. Conclusions. We have developed a reproducible immunopotency assay to measure allogeneic MSC-mediated suppression of CD4+ T cells. Additional studies may be warranted to determine how these in vitro assay results may correlate with other immunomodulatory properties of MSCs, in addition to evaluating the ability of this assay to predict in vivo efficacy.
引用
收藏
页码:140 / 151
页数:12
相关论文
共 50 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Mesenchymal stem cells: immune evasive, not immune privileged [J].
Ankrum, James A. ;
Ong, Joon Faii ;
Karp, Jeffrey M. .
NATURE BIOTECHNOLOGY, 2014, 32 (03) :252-260
[3]   Mesenchymal stem cells in hematopoietic stem cell transplantation [J].
Battiwalla, Minoo ;
Hematti, Peiman .
CYTOTHERAPY, 2009, 11 (05) :503-515
[4]   Mesenchymal stem cells: Revisiting history, concepts, and assays [J].
Bianco, Paolo ;
Robey, Pamela Gehron ;
Simmons, Paul J. .
CELL STEM CELL, 2008, 2 (04) :313-319
[5]   MESENCHYMAL STEM-CELLS [J].
CAPLAN, AI .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650
[6]   IDO-Independent Suppression of T Cell Effector Function by IFN-γ-Licensed Human Mesenchymal Stromal Cells [J].
Chinnadurai, Raghavan ;
Copland, Ian B. ;
Patel, Seema R. ;
Galipeau, Jacques .
JOURNAL OF IMMUNOLOGY, 2014, 192 (04) :1491-1501
[7]   The role of mesenchymal stem cells in haemopoiesis [J].
Dazzi, Francesco ;
Ramasamy, Rajesh ;
Glennie, Sarah ;
Jones, Simon P. ;
Roberts, Irene .
BLOOD REVIEWS, 2006, 20 (03) :161-171
[8]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[9]   A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy [J].
Forbes, Geoffrey M. ;
Sturm, Marian J. ;
Leong, Rupert W. ;
Sparrow, Miles P. ;
Segarajasingam, Dev ;
Cummins, Adrian G. ;
Phillips, Michael ;
Herrmann, Richard P. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (01) :64-71
[10]   The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group [J].
Freedman, Mark S. ;
Bar-Or, Amit ;
Atkins, Harold L. ;
Karussis, Dimitrios ;
Frassoni, Francesco ;
Lazarus, Hillard ;
Scolding, Neil ;
Slavin, Shimon ;
Le Blanc, Katarina ;
Uccelli, Antonio .
MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (04) :503-510